Trial Profile
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Coronary arteriosclerosis
- Focus Therapeutic Use
- 15 Feb 2017 Planned number of patients changed from 100 to 194, according to trial design published in the Trials.
- 19 Feb 2015 New trial record